Ann Lee-Karlon named CEO of EpiBiologics
Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio
Antibody-based protein degradation company EpiBiologics Inc. named Ann Lee-Karlon president, CEO and a board member. Lee-Karlon, an 18-year veteran of Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), was most recently COO of Altos Labs Inc. The company also said it raised an additional $23 million in a series A round backed by new investors Digitalis Ventures and Taiho Ventures and existing investor Codon Capital, bringing the round total to $73 million.
Franz-Werner Haas became CEO at LimmaTech Biologics AG, a vaccine developer. Haas joins from CureVac N.V. (NASDAQ:CVAC), where he held several roles over 11 years, including CEO, COO and chief corporate officer. The company also said it in-licensed rights from GSK plc (LSE:GSK; NYSE:GSK) to develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis, for which Phase I/II results are expected this year. ...